# BPC-157 TB-500: What the Wolverine Research Blend Actually Is > BPC-157 TB-500 is the two-peptide "Wolverine" blend: BPC-157 paired with TB-500. A research digest of what each constituent has been studied for, with the gaps marked and every claim cited. BPC-157 supplies a local cytoprotective and pro-angiogenic signal; TB-500 supplies an actin-sequestering cell-migration signal. Both are preclinical, both unapproved, and no controlled trial has tested the two together. Here is what the literature shows and where it stops. ## Two peptides, two mechanisms, one repair goal BPC-157 TB-500 is the research-community name for a two-peptide pairing marketed and discussed as a tissue-repair "stack." It is not a single chemical entity. There is no combined molecular weight, no CAS number for the pair, and no standardized BPC-157:TB-500 ratio. The blend is two distinct synthetic peptides handled together, and the most useful way to read it is one constituent at a time. BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV (~1419.5 Da), derived from a partial sequence of a protein found in human gastric juice [1]. In the blend it acts as the local cytoprotective and pro-angiogenic leg: it up-regulates VEGFR2, modulates the nitric-oxide system, and sensitizes tendon fibroblasts to growth-hormone-driven proliferation [2][5]. TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ (~889 Da), corresponding to residues 17-23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4 [8]. Its proposed role is cytoskeletal: the LKKTETQ helix binds monomeric G-actin one-to-one, regulating the actin dynamics that drive cell migration and re-epithelialization [3][4]. One caveat travels with TB-500 everywhere on this site: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the 7-mer [4]. The two peptides are structurally unrelated, different in size, and act through largely non-overlapping pathways. That non-overlap is exactly the argument the blend rests on — and exactly why "synergy" remains a theoretical extrapolation rather than a measured result. This site reads each leg separately across the [BPC-157 and TB-500 angiogenesis research](/angiogenesis-research), the dosing context, and the safety record, and indexes the common questions in one place. ## Why the research community pairs BPC-157 with TB-500 The pairing rationale is complementary coverage. BPC-157's local angiogenic and cytoprotective signal is proposed to handle the perfusion-and-survival side of repair, while TB-500's cytoskeletal cell-migration signal is proposed to handle the cell-movement side — so the two are said to cover different stages of tissue repair from different directions [2][4]. That logic is clean on paper. The evidence underneath it is not a combination study. No peer-reviewed work has defined a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 36 studies — 35 preclinical, only one human — found "no clinical safety data," and makes no mention of TB-500 or any blend at all [9]. The combination is an extrapolation from two separately characterized mechanisms, not a finding. ### Why BPC-157 and TB-500 Are Combined The rationale is complementary mechanisms: BPC-157's local angiogenic and cytoprotective signal is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of tissue repair [2][4]. Critically, no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint for the two given together [9]. ### Why BPC-157 and TB-500 Are Combined (the Wolverine stack) The stack pairs a perfusion-and-survival signal with a cell-migration signal. BPC-157 promotes VEGFR2-driven angiogenesis and fibroblast survival [2][7]; TB-500/Thymosin Beta-4 promotes the actin-regulated migration of endothelial, epithelial, and progenitor cells [3][4]. The pairing is mechanistically coherent and clinically unproven — there is no controlled combination trial. The blend is also distributed through non-regulated channels, so product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated "Wolverine" material are not guaranteed [8]. For where regulated access actually stands, see [Wolverine legal status and FDA 503A category](/legal-status). ## What the blend is studied for The research base for both constituents is overwhelmingly preclinical and overwhelmingly rodent. For BPC-157, the most-cited single result is tendon: 10 microg/kg accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures, and in vitro reversed 4-hydroxynonenal-induced growth inhibition of tendocytes into stimulation [1]. For TB-500's parent protein, a consolidated review describes Thymosin Beta-4 binding actin, mobilizing cells, reducing myofibroblast number, limiting inflammation, and promoting angiogenesis [4]. These are single-compound, animal-model findings. The blend itself has no controlled efficacy study, and the human record for the individual constituents is thin: BPC-157 has three small pilot studies, and "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide [9]. The [BPC-157 and TB-500 dosage in animal models](/dosage) is summarized in research terms, the [side effects and safety signals](/faq#side-effects) are catalogued honestly, and the [frequently asked questions](/faq) collect the rest in one index. ### What Is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein [1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 [8]. The "Wolverine" blend pairs the two as a research-community tissue-repair stack; it is not a single chemical entity and is not an approved product anywhere. ### What Is the Wolverine Peptide Blend? The Wolverine peptide blend is a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It has no CAS number, no standardized ratio, and no approved indication [8]. Commercial vials are commonly labeled with a combined per-vial mass (e.g. 10 mg BPC-157 + 10 mg TB-500), but no standardized composition is clinically validated. ### What the Blend Is Studied For Preclinical research on the two constituents covers tendon, ligament, muscle, and bone repair, wound and soft-tissue healing, and angiogenesis [1][4]. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study, and the 2025 systematic review of BPC-157 graded the evidence at level IV-V, the lowest tiers [9]. ## Two compounds, told apart Reading the blend well means keeping its two halves distinct. The site marks every finding with the constituent it belongs to — BPC-157 on one channel, TB-500 on the other — so a reader sees at a glance which leg of the blend an evidence point comes from. ### How BPC-157 Works Compared to TB-500 BPC-157 supplies a local cytoprotective and pro-angiogenic signal — VEGFR2-Akt-eNOS up-regulation, nitric-oxide modulation, and growth-hormone-receptor sensitization of tendon fibroblasts [2][5][6]. TB-500 supplies an intracellular actin-sequestration signal: 1:1 G-actin binding via the LKKTETQ motif that regulates cell migration [3]. They act through complementary but largely non-overlapping pathways. ### BPC-157 vs TB-500: Two Distinct Compounds They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein acting via VEGFR2/nitric-oxide and growth-hormone-receptor pathways [1][2][5]; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting by sequestering G-actin [3][8]. Different sequences, different sizes, different mechanisms. ### What Is the Difference Between BPC-157 and TB-500? They are structurally unrelated peptides. BPC-157 (GEPPPGKPADDAGLV, ~1419.5 Da) acts via VEGFR2-Akt-eNOS and growth-hormone-receptor signaling [1][2]; TB-500 (Ac-LKKTETQ, ~889 Da) acts by sequestering monomeric G-actin through its LKKTETQ motif [3][8]. Different sequence, different size, different mechanism — paired only by a shared tissue-repair rationale. --- An access-and-evidence console for the BPC-157 and TB-500 record — each constituent logged to its own studies, each blend-level gap left visible, with no clinic behind the panel and nothing here to dispense.